Abciximab
Lornoxicam may increase the anticoagulant activities of Abciximab.
Abiraterone
The metabolism of Lornoxicam can be decreased when combined with Abiraterone.
Acebutolol
Lornoxicam may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Aceclofenac.
Acemetacin
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Acemetacin.
Acenocoumarol
Lornoxicam may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Acetaminophen.
Acetyl Sulfisoxazole
The metabolism of Lornoxicam can be decreased when combined with Acetyl sulfisoxazole.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Lornoxicam.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.
Aliskiren
Lornoxicam may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Lornoxicam.
Alprenolol
Lornoxicam may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Lornoxicam.
Amcinonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Amcinonide.
Amikacin
Lornoxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Lornoxicam may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Lornoxicam can be decreased when combined with Amiodarone.
Ancrod
Lornoxicam may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Androstenedione.
Anhydrous Tacrolimus
Lornoxicam may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.
Antithrombin III
Lornoxicam may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Lornoxicam may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Lornoxicam can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Lornoxicam.
Apixaban
Lornoxicam may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Lornoxicam.
Aprepitant
The metabolism of Lornoxicam can be increased when combined with Aprepitant.
Arbekacin
Lornoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Lornoxicam may increase the anticoagulant activities of Ardeparin.
Argatroban
Lornoxicam may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Lornoxicam may increase the anticoagulant activities of Argatroban.
Asenapine
Lornoxicam may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ginseng.
Atenolol
Lornoxicam may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Lornoxicam.
azficel-T
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Lornoxicam.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Lornoxicam.
Bazedoxifene
Lornoxicam may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Lornoxicam may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lornoxicam.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Lornoxicam.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Lornoxicam.
Betamethasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Betamethasone.
Betaxolol
Lornoxicam may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Lornoxicam.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lornoxicam.
Bisoprolol
Lornoxicam may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Lornoxicam may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Lornoxicam may decrease the antihypertensive activities of Bopindolol.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.
Budesonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Lornoxicam.
Bupranolol
Lornoxicam may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lornoxicam.
Capecitabine
The metabolism of Lornoxicam can be decreased when combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Captopril.
Carbamazepine
The metabolism of Lornoxicam can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lornoxicam.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lornoxicam.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Lornoxicam.
Carteolol
Lornoxicam may decrease the antihypertensive activities of Carteolol.
Carvedilol
Lornoxicam may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Lornoxicam.
Celiprolol
Lornoxicam may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Lornoxicam can be increased when it is combined with Ceritinib.
Certoparin
Lornoxicam may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Lornoxicam.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.
Chlorotrianisene
Lornoxicam may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lornoxicam.
Cholecalciferol
The metabolism of Lornoxicam can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lornoxicam.
Ciclesonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Cilazapril.
Cinoxacin
Lornoxicam may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Lornoxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Cisplatin.
Citalopram
Citalopram may increase the antiplatelet activities of Lornoxicam.
Citric Acid
Lornoxicam may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Lornoxicam may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Lornoxicam.
Clotrimazole
The metabolism of Lornoxicam can be decreased when combined with Clotrimazole.
Colesevelam
Colesevelam can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Cortisone acetate.
Crisaborole
The metabolism of Lornoxicam can be decreased when combined with Crisaborole.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Lornoxicam.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lornoxicam.
Cyclosporine
Lornoxicam may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
Lornoxicam may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Lornoxicam can be decreased when it is combined with Dabrafenib.
Dalteparin
Lornoxicam may increase the anticoagulant activities of Dalteparin.
Danaparoid
Lornoxicam may increase the anticoagulant activities of Danaparoid.
Deferasirox
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Deflazacort.
Delavirdine
The metabolism of Lornoxicam can be decreased when combined with Delavirdine.
Desipramine
Lornoxicam may decrease the antihypertensive activities of Desipramine.
Desirudin
Lornoxicam may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Lornoxicam.
Dexamethasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lornoxicam.
Dextran
Lornoxicam may increase the anticoagulant activities of Dextran.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Lornoxicam.
Dicumarol
Lornoxicam may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Lornoxicam may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Lornoxicam may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.
Difluprednate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Lornoxicam.
Dihydrostreptomycin
Lornoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Lornoxicam.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lornoxicam.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lornoxicam.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.
Dothiepin
The metabolism of Lornoxicam can be decreased when combined with Dosulepin.
Drospirenone
Lornoxicam may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Droxicam.
Duloxetine
Duloxetine may increase the antiplatelet activities of Lornoxicam.
Edetic Acid
Lornoxicam may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Lornoxicam may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Lornoxicam can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalaprilat.
Enoxacin
Lornoxicam may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Lornoxicam may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Lornoxicam may increase the anticoagulant activities of Enoxaparin.
Eplerenone
Lornoxicam may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.
Equol, (-)-
Lornoxicam may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Lornoxicam.
Esmolol
Lornoxicam may decrease the antihypertensive activities of Esmolol.
Estradiol
Lornoxicam may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Lornoxicam may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Lornoxicam may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Lornoxicam may increase the thrombogenic activities of Estradiol valerate.
Estriol
Lornoxicam may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Lornoxicam may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Lornoxicam may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lornoxicam.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lornoxicam.
Ethinyl Estradiol
Lornoxicam may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Lornoxicam may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Lornoxicam.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Lornoxicam.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Lornoxicam.
Etravirine
The metabolism of Lornoxicam can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lornoxicam.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Lornoxicam.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Lornoxicam.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Lornoxicam.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Lornoxicam.
Fish Oils
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fish oil.
Fleroxacin
Lornoxicam may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Lornoxicam.
Floxuridine
The metabolism of Lornoxicam can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Lornoxicam can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fludrocortisone.
Fluindione
Lornoxicam may increase the anticoagulant activities of Fluindione.
Flumequine
Lornoxicam may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluorometholone.
Fluorouracil
The metabolism of Lornoxicam can be decreased when combined with Fluorouracil.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Lornoxicam.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lornoxicam.
Fluticasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone propionate.
Fluvastatin
The metabolism of Lornoxicam can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Lornoxicam can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Lornoxicam.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Lornoxicam.
Fondaparinux sodium
Lornoxicam may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Fosinopril.
Fosphenytoin
The metabolism of Lornoxicam can be increased when combined with Fosphenytoin.
Framycetin
Lornoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Lornoxicam.
Gatifloxacin
Lornoxicam may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Lornoxicam may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Lornoxicam.
Gemfibrozil
The metabolism of Lornoxicam can be decreased when combined with Gemfibrozil.
Gemifloxacin
Lornoxicam may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Lornoxicam may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Lornoxicam may increase the thrombogenic activities of Genistein.
Gentamicin
Lornoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ginseng.
Grepafloxacin
Lornoxicam may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.
Heparin
Lornoxicam may increase the anticoagulant activities of Heparin.
Hydralazine
Lornoxicam may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lornoxicam.
Hydrocortisone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lornoxicam.
Ibandronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Lornoxicam.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.
Imidapril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.
Indinavir
The metabolism of Lornoxicam can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Lornoxicam can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Lornoxicam.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.
Irbesartan
The metabolism of Lornoxicam can be decreased when combined with Irbesartan.
Kanamycin
Lornoxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Lornoxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Lornoxicam.
Ketoconazole
The metabolism of Lornoxicam can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Lornoxicam.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ginseng.
Labetalol
Lornoxicam may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Lornoxicam.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Lornoxicam.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Lornoxicam.
Lepirudin
Lornoxicam may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Lornoxicam may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Lornoxicam may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Lornoxicam may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Lornoxicam may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Lornoxicam.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lornoxicam.
Lisinopril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Lornoxicam.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Lornoxicam.
Lomefloxacin
Lornoxicam may increase the neuroexcitatory activities of Lomefloxacin.
Losartan
The metabolism of Lornoxicam can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Loteprednol.
Lovastatin
The metabolism of Lornoxicam can be decreased when combined with Lovastatin.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Lornoxicam.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lornoxicam.
Lumacaftor
The serum concentration of Lornoxicam can be decreased when it is combined with Lumacaftor.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.
Manidipine
The metabolism of Lornoxicam can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Lornoxicam.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.
Medronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lornoxicam.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.
Mepindolol
Lornoxicam may decrease the antihypertensive activities of Mepindolol.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Lornoxicam.
Mestranol
Lornoxicam may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Lornoxicam.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lornoxicam.
Methylprednisolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Methylprednisolone.
Metipranolol
Lornoxicam may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.
Metoprolol
Lornoxicam may decrease the antihypertensive activities of Metoprolol.
Midostaurin
The metabolism of Lornoxicam can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Lornoxicam can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Lornoxicam.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Lornoxicam.
Moexipril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Lornoxicam.
Moxifloxacin
Lornoxicam may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.
Nabilone
The metabolism of Lornoxicam can be decreased when combined with Nabilone.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Lornoxicam.
Nadolol
Lornoxicam may decrease the antihypertensive activities of Nadolol.
Nadroparin
Lornoxicam may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Lornoxicam.
Nalidixic Acid
Lornoxicam may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Lornoxicam.
Nebivolol
Lornoxicam may decrease the antihypertensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the antiplatelet activities of Lornoxicam.
Neomycin
Lornoxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Lornoxicam.
Netilmicin
Lornoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nicardipine
The metabolism of Lornoxicam can be decreased when combined with Nicardipine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lornoxicam.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.
Norfloxacin
Lornoxicam may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lornoxicam.
Ofloxacin
Lornoxicam may increase the neuroexcitatory activities of Ofloxacin.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Lornoxicam.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Lornoxicam.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Lornoxicam is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Lornoxicam can be decreased when combined with Omeprazole.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.
Oxprenolol
Lornoxicam may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Lornoxicam.
Pamidronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Parecoxib.
Paromomycin
Lornoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Lornoxicam.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Lornoxicam.
Pefloxacin
Lornoxicam may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Lornoxicam may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Lornoxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Lornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Perindopril.
Phenindione
Lornoxicam may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Lornoxicam can be increased when combined with Phenobarbital.
Phenprocoumon
Lornoxicam may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lornoxicam.
Phenytoin
The metabolism of Lornoxicam can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lornoxicam.
Pindolol
Lornoxicam may decrease the antihypertensive activities of Pindolol.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Lornoxicam.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.
Plazomicin
Lornoxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polyestradiol Phosphate
Lornoxicam may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Lornoxicam.
Pomalidomide
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Pomalidomide.
Potassium Citrate
Lornoxicam may increase the anticoagulant activities of Potassium Citrate.
Practolol
Lornoxicam may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Lornoxicam.
Prasterone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Pregnenolone.
Primidone
The metabolism of Lornoxicam can be increased when combined with Primidone.
Probenecid
The serum concentration of Lornoxicam can be increased when it is combined with Probenecid.
Promestriene
Lornoxicam may increase the thrombogenic activities of Promestriene.
Propafenone
Lornoxicam may decrease the antihypertensive activities of Propafenone.
Propranolol
Lornoxicam may decrease the antihypertensive activities of Propranolol.
protein C, human
Lornoxicam may increase the anticoagulant activities of Protein C.
protein S, human
Lornoxicam may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Lornoxicam may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Lornoxicam can be decreased when combined with Pyrimethamine.
Quinapril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Quinapril.
Quinestrol
Lornoxicam may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Lornoxicam.
Quinine
The metabolism of Lornoxicam can be decreased when combined with Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ramipril.
Rescinnamine
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.
Reviparin
Lornoxicam may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Lornoxicam may increase the anticoagulant activities of Reviparin.
Rifampin
The metabolism of Lornoxicam can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Lornoxicam can be increased when combined with Rifapentine.
Rimexolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.
Rivaroxaban
Lornoxicam may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Lornoxicam.
Rosoxacin
Lornoxicam may increase the neuroexcitatory activities of Rosoxacin.
Rucaparib
The metabolism of Lornoxicam can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Lornoxicam.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Lornoxicam.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Lornoxicam.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Lornoxicam.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Lornoxicam.
Secobarbital
The metabolism of Lornoxicam can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Lornoxicam.
Sertraline
Sertraline may increase the antiplatelet activities of Lornoxicam.
Sildenafil
The metabolism of Lornoxicam can be decreased when combined with Sildenafil.
Sisomicin
Lornoxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Lornoxicam may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Lornoxicam.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Lornoxicam.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Lornoxicam.
Sorafenib
The metabolism of Lornoxicam can be decreased when combined with Sorafenib.
Sotalol
Lornoxicam may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Lornoxicam may increase the neuroexcitatory activities of Sparfloxacin.
Spirapril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Spirapril.
Spironolactone
Lornoxicam may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Lornoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sulfadiazine
The metabolism of Lornoxicam can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Lornoxicam can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lornoxicam.
Sulfisoxazole
The metabolism of Lornoxicam can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Lornoxicam.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.
synthetic conjugated estrogens, A
Lornoxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Lornoxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Lornoxicam may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Lornoxicam.
Talinolol
Lornoxicam may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Lornoxicam.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.
Temafloxacin
Lornoxicam may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Lornoxicam.
Terbutaline
Lornoxicam may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Lornoxicam may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Lornoxicam.
Tertatolol
Lornoxicam may decrease the antihypertensive activities of Tertatolol.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lornoxicam.
Tibolone
Lornoxicam may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Lornoxicam can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Lornoxicam can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Tiludronic acid.
Timolol
Lornoxicam may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Lornoxicam may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Tixocortol.
Tobramycin
Lornoxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolbutamide
The metabolism of Lornoxicam can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lornoxicam.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Lornoxicam.
Trandolapril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Lornoxicam.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Lornoxicam.
Triamcinolone
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Triamcinolone.
Triamterene
Lornoxicam may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Lornoxicam.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lornoxicam.
Trimethoprim
The metabolism of Lornoxicam can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Lornoxicam may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Trolamine salicylate.
Trovafloxacin
Lornoxicam may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Lornoxicam may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Lornoxicam.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Lornoxicam.
Valproate
The metabolism of Lornoxicam can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Lornoxicam can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Lornoxicam can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Lornoxicam.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Lornoxicam.
Voriconazole
The metabolism of Lornoxicam can be decreased when combined with Voriconazole.
Warfarin
Lornoxicam may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Lornoxicam can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Lornoxicam.
Zofenopril
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.
